Short answer
Schrodinger, Inc. (SDGR) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $59M (down 1.6% year over year) with net income of −$60M.
Q1 2026 key financials · XBRL
- Revenue
- $59M
- −1.6% YoY
- Net income
- −$60M
- −0.4% YoY
- Operating margin
- -83.3%
- Gross margin
- 50.4%
- EPS (diluted)
- −$0.81
- +1.2% YoY
Source: XBRL data from the Schrodinger, Inc. (SDGR) Q1 2026 10-Q on SEC EDGAR. USD.
Schrodinger, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $58.6M, down 2% YoY from $59.6M
- Net loss $60.0M vs $59.8M YoY
- Software ACV $28.4M vs $25.4M YoY
- Hosted-software transition expected to pressure near-term revenue recognition
- Planned proprietary clinical investment limited to SGR-1505 and SGR-3515 Phase 1 trials
Risk Factors
- No material-change statement provided; filing text appears truncated before comparative 10-K disclosures
- Operating loss risk: Q1 2026 net loss $60.0 million and accumulated deficit $688.8 million
- Hosted-software transition: near-term revenue decline from ratable recognition replacing point-in-time recognition
- Drug-development regulatory risk: SGR-1505 and SGR-3515 remain in Phase 1 dose-escalation trials
- Liquidity risk: $406.4 million cash, restricted cash, and marketable securities expected to fund operations through at least 24 months
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Schrodinger, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.